Shares of Eli Lilly and Co. LLY tumbled 9.6% in premarket trading Wednesday, after the drug maker reported third-quarter profit and revenue that missed expectations by wide margins, as sales of ...
Eli Lilly And Co LLY experienced a 1.37% increase in pre-market trading on Wednesday, as per Benzinga Pro. This uptick occurs ...
Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...
6don MSN
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug ...
The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...
Eli Lilly (NYSE: LLY) shares plunged around 10% in premarket trading on Wednesday after it reported third-quarter earnings that fell short of analyst expectations ...
Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback